X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
AJANTA PHARMA Fact Sheet, AJANTA PHARMA Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA Fact Sheet   (AJPH)

Here is the latest financial fact sheet of AJANTA PHARMA. For more details, see the AJANTA PHARMA quarterly results and AJANTA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

AJANTA PHARMA Price History

Price Rs 950.5
Mkt Cap Rs m 83,596
Vol '000 9.5
P/E X 17.8
P/CF X 15.8
EPS (TTM) Rs 53.3
% ch % -2.0
No. of shares m 87.95
% ch week % -7.3
% ch 1-mth % -13.3
% ch 12-mth % -35.9
52 week H/L Rs 1,592.0/897.6
(As on Jul 17, 2018 09:41:00 AM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

AJANTA PHARMA Financials

No. of Mths
Year Ending
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
5-Yr Chart
Click to enlarge
AJANTA PHARMA EQUITY SHARE DATA
High Rs1,1777791,7202,0981,818 
Low Rs6252991,1031,3511,106 
Sales per share (Unadj.) Rs340.8166.1195.3223.4239.5 
Earnings per share (Unadj.) Rs66.034.946.857.152.8 
Diluted earnings per shareRs26.635.247.357.653.3 
Cash flow per share (Unadj.) Rs78.340.851.864.059.5 
Dividends per share (Unadj.) Rs10.006.008.0013.000 
Adj. dividends per shareRs4.036.058.0713.120.00 
Dividend yield (eoy) %1.11.10.60.80 
Book value per share (Unadj.) Rs167.394.8134.2176.6230.0 
Adj. book value per shareRs67.595.6135.4178.2232.1 
Shares outstanding (eoy) m35.4688.7188.7788.7788.77 
Bonus/Rights/Conversions  B1:2,ESOSFV2--- 
Price / Sales ratio x2.63.27.27.76.1 
Avg P/E ratio x13.715.430.130.227.7 
P/CF ratio (eoy) x11.513.227.226.924.6 
Price / Book Value ratio x5.45.710.59.86.4 
Dividend payout %15.217.217.122.80 
Avg Mkt Cap Rs m31,95147,797125,299153,062129,782 
No. of employees `000NANANANA6.8 
Total wages/salary Rs m1,5702,0062,5662,9543,765 
Avg. sales/employee Rs ThNMNMNMNM3,128.4 
Avg. wages/employee Rs ThNMNMNMNM554.0 
Avg. net profit/employee Rs ThNMNMNMNM689.7 
AJANTA PHARMA INCOME DATA
Net Sales Rs m12,08314,73617,34019,83321,258 
Other income Rs m137168212239242 
Total revenues Rs m12,22114,90417,55120,07121,499 
Gross profit Rs m3,6885,0525,8716,8696,584 
Depreciation Rs m439516444612596 
Interest Rs m875949144 
Profit before tax Rs m3,2994,6455,5896,4826,226 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m0-85000 
Tax Rs m9601,4621,4331,4131,539 
Profit after tax Rs m2,3393,0994,1565,0684,686 
Gross profit margin %30.534.333.934.631.0 
Effective tax rate %29.131.525.621.824.7 
Net profit margin %19.421.024.025.622.0 
AJANTA PHARMA BALANCE SHEET DATA
Current assets Rs m5,2016,3347,6398,50612,236 
Current liabilities Rs m2,7542,4962,7152,4673,461 
Net working cap to sales %20.226.028.430.541.3 
Current ratio x1.92.52.83.43.5 
Inventory Days Days4739433960 
Debtors Days Days6164785984 
Net fixed assets Rs m3,7294,5836,9149,28411,140 
Share capital Rs m177177177177177 
"Free" reserves Rs m5,6508,18611,73215,50020,237 
Net worth Rs m5,9338,41111,90915,67720,414 
Long term debt Rs m5233331491010 
Total assets Rs m9,49411,43414,88018,47724,486 
Interest coverage x38.879.5115.3477.61,519.4 
Debt to equity ratio x0.10000 
Sales to assets ratio x1.31.31.21.10.9 
Return on assets %25.627.628.327.519.2 
Return on equity %39.436.834.932.323.0 
Return on capital %52.452.846.841.430.5 
Exports to sales %54.754.754.900 
Imports to sales %5.04.46.000 
Exports (fob) Rs m6,6068,0629,52700 
Imports (cif) Rs m6026531,03800 
Fx inflow Rs m6,8968,49410,42211,47711,667 
Fx outflow Rs m1,1681,2471,6782,2061,616 
Net fx Rs m5,7287,2478,7449,27110,052 
AJANTA PHARMA CASH FLOW
From Operations Rs m 2,124 2,794 3,261 6,093 2,854 
From Investments Rs m -1,878 -1,584 -2,091 -3,831 -2,604 
From Financial Activity Rs m -201 -1,052 -1,173 -2,018 -2 
Net Cashflow Rs m 45 159 -3 244 248 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 73.8%
Foreign collaborators 0.0%
Indian inst/Mut Fund 1.6%
FIIs 7.6%
ADR/GDR 0.0%
Free float 17.0%
Shareholders 20,968
Pledged promoter(s) holding 4.4%
 

Company Information

REGD OFF Ajanta House, Charkop, Kandivli (W), Mumbai - 400 067
E-MAIL deodatta.pandit@ajantapharma.com WEB www.ajantapharma.com
TELEPHONE (022) 66061000 FAX (022) 6606 1200
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
AUDITOR Kapoor & Parekh Assoc.
CHM: Mannalal B. Agrawal COMP SEC: Gaurang Shah YEAR OF INC: 1979 BSE CODE: 532331 FV (Rs): 5 DIV YIELD (%): -

More Pharmaceuticals Company Fact Sheets:   SANOFI INDIA  PANACEA BIOTECH  INDOCO REMEDIES  SUVEN LIFE  ORCHID PHARMA LTD  

Compare AJANTA PHARMA With:   SANOFI INDIA  PANACEA BIOTECH  INDOCO REMEDIES  SUVEN LIFE  ORCHID PHARMA LTD  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade in Red, Inflation on an Uptrend, and Top Stocks in Action(Pre-Open)

On Monday, share markets in India opened on a positive note and ended the day in red after a dull day of trading.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Real Truth About India's FDI, Beyond WhatsApp(Vivek Kaul's Diary)

Jul 4, 2018

The FDI numbers do not look very impressive once we adjust for repatriations as well as the overall growth in the economy.

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AJANTA PHARMA

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS